Press Releases Kyowa Kirin Co., Ltd. OTC Markets

Equities

KYKOY

US50156R1077

Delayed OTC Markets Other stock markets 09:50:18 2024-07-16 am EDT			5-day change	1st Jan Change
19.85 ^USD	+0.27%		0.00%	+22.18%

Jul. 03	Kyowa Kirin Buys Back Shares	MT
Jul. 02	Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kyowa Kirin : Announces Application for Additional Formulation of “LUMICEF® Subcutaneous Injection 210 mg Pen” in Japan	Jun. 28	PU
Kyowa Kirin : Announces Approval for Partial Change of Approved Indication of G-Lasta® for the Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation in Japan (243KB)	May. 17	PU
Kyowa Kirin : Transcript of Results Briefing Fiscal 2024 First Quarter (0B)	May. 09	PU
Kyowa Kirin : Results Presentation Fiscal 2024 First Quarter (0B)	May. 07	PU
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List	May. 06	AQ
Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ (istradefylline) and Other Parkinson's Disease Add-On Therapies	Apr. 15	AQ
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome	Apr. 15	BU
Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024	Mar. 11	AQ
Kyowa Kirin : Partial Corrections to “Notice of Convocation of the 101st Ordinary General Meeting of Shareholders” (0B)	Mar. 05	PU
Kyowa Kirin Co., Ltd - Notice regarding Completion of Share Acquisition of Orchard Therapeutics plc	Jan. 26	AQ
Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases	Jan. 24	BU
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases	Jan. 24	AQ
Eczema Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 \| LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, AstraZeneca, Kyowa Kirin, and Others	Dec. 07	AQ
Kyowa Kirin : Transcript of Results Presentation Fiscal 2023 Third Quarter (text) (0B)	Nov. 06	PU
Kyowa Kirin : Consolidated Financial Summary (IFRS) Fiscal 2023 Third Quarter (0B)	Nov. 01	PU
Kyowa Kirin : Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2023 Third Quarter (0B)	Nov. 01	PU
Kyowa Kirin : Results Presentation Fiscal 2023 Third Quarter (0B)	Nov. 01	PU
Kyowa Kirin : Announces Presentations of the Results of Phase 3 Studies of PHOZEVEL® for Patients with Hyperphosphatemia Undergoing Dialysis in Japan at the American Society of Nephrology Meeting (291KB)	23-10-17	PU
Kyowa Kirin Announces Three Abstracts and A Symposium at the European Academy of Dermatology and Venereology Congress 2023	23-10-11	AQ
Kyowa Kirin to Acquire Orchard Therapeutics	23-10-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kyowa Kirin Co., Ltd. OTC Markets

Equities

KYKOY

US50156R1077

Press Releases

Filters